Accelerate Diagnostics, Inc.
|Company Name||Accelerate Diagnostics, Inc.|
On October 21, 2022, after the market closed, Accelerate disclosed that it had received a request from the U.S. Food and Drug Administration to immediately discontinue the marketing and distribution of its Accelerate Arc system and related BC Kit for a particular diagnostic use.
On this news, Accelerate’s stock fell $0.62, or 39%, to close at $0.97 per share on October 24, 2022, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Accelerate Diagnostics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.